To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group,
Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63
in Healthy Subjects.